A Real-World Clinical Trial Evaluating Satisfaction and Experiences with a Dexamethasone Mouth Film Compared to Corticosteroid Tablets as Rescue Medication for Moderate to Severe Acute Allergic Reactions
Journal of Market Access & Health Policy · 27.07.2026 · 14 (3) · 43
DOI: 10.3390/jmahp14030043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Market Access & Health Policy, online erschienen am 27.07.2026. Verfasst von Leif Bjermer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Allergology, Lund University, SE-221 85 Lund, Sweden. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AcuCort AB.
Abstract (Originalsprache)
Despite the need for immediate treatment during acute allergic reactions (AARs), many patients do not consistently carry medication. A new mouth-dissolving dexamethasone film offers a portable, easily administered alternative to corticosteroid tablets. This non-randomized, open-label, low-interventional real-world trial assessed satisfaction (accessibility and safety/security) with the mouth film versus betamethasone tablets in adults prescribed tablets for moderate to severe AARs at a Swedish primary care center. Over six months, participants had access to both treatments and reported monthly via an electronic diary; qualitative responses were converted to Likert scales where applicable. Of 50 enrolled, 44 provided diary data (mean age 50 years, 74% female, 58% had an epinephrine autoinjector). In total, 189 responses were collected: 98% stated that the participant was satisfied or very satisfied with mouth film accessibility versus 58% for tablets (mean Likert scores 3.5–3.7 vs. 2.5–2.8; p < 0.001). A higher feeling of safety with the mouth film versus tablets was reported in 78% of responses and improved medication carriage compliance in 77%. At six months, 69% preferred the film. Of 18 AARs in total reported by 13 participants, the mouth film was chosen for treatment of 16 (11 participants); in 94%, the mouth film was found immediately accessible, and in 94%, the efficacy was rated as good or very good. In conclusion, the mouth film improved perceived accessibility, safety/security, and medication-carriage compliance compared with tablets for the treatment of AARs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine and Allergology, Lund University, SE-221 85 Lund, Sweden.
- Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, SE-171 76 Stockholm, Sweden.
- Acucort AB, SE-223 81 Lund, Sweden.
- The Swedish Institute for Health Economics, SE-223 61 Lund, Sweden.
- Kåbohälsan, SE-752 37 Uppsala, Sweden.
ORCID-Profile: Göran Tornling, Karin Wahlberg, Jonas Hjelmgren
Förderung
- AcuCort AB
Zitieren
APA
Bjermer, L., Tornling, G., Kereki, J., Wahlberg, K., Javizian, B., & Hjelmgren, J. (2026). A Real-World Clinical Trial Evaluating Satisfaction and Experiences with a Dexamethasone Mouth Film Compared to Corticosteroid Tablets as Rescue Medication for Moderate to Severe Acute Allergic Reactions. Journal of Market Access & Health Policy, 14(3), 43. https://doi.org/10.3390/jmahp14030043
Vancouver
Bjermer L, Tornling G, Kereki J, Wahlberg K, Javizian B, Hjelmgren J. A Real-World Clinical Trial Evaluating Satisfaction and Experiences with a Dexamethasone Mouth Film Compared to Corticosteroid Tablets as Rescue Medication for Moderate to Severe Acute Allergic Reactions. Journal of Market Access & Health Policy. 2026;14(3):43. doi:10.3390/jmahp14030043
BibTeX
@article{Bjermer2026,
author = {Bjermer, Leif and Tornling, Göran and Kereki, James and Wahlberg, Karin and Javizian, Bahram and Hjelmgren, Jonas},
title = {A Real-World Clinical Trial Evaluating Satisfaction and Experiences with a Dexamethasone Mouth Film Compared to Corticosteroid Tablets as Rescue Medication for Moderate to Severe Acute Allergic Reactions},
journal = {Journal of Market Access & Health Policy},
year = {2026},
volume = {14},
number = {3},
pages = {43},
doi = {10.3390/jmahp14030043}
}
EUVIMED